Background-Recently, evidence has emerged that small-conductance Ca 2ϩ -activated K ϩ (SK) channels are predominantly expressed in the atria in a number of species including human. In rat, guinea pig, and rabbit ex vivo and in vivo models of atrial fibrillation (AF), we used 3 different SK channel inhibitors, UCL1684, N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (ICA), and NS8593, to assess the hypothesis that pharmacological inhibition of SK channels is antiarrhythmic. Methods and Results-In isolated, perfused guinea pig hearts, AF could be induced in all control hearts (nϭ7) with a combination of 1 mol/L acetylcholine combined with electric stimulation. Pretreatment with 3 mol/L NS8593, which had no effect on QT interval, prolonged the atrial effective refractory period by 37.1Ϯ7.7% (PϽ0.001) and prevented acetylcholine-induced AF (PϽ0.001, nϭ7). After AF induction, perfusion with NS8593 (10 mol/L), UCL1684
T he use of conventional class III agents that decrease K ϩ currents has been limited because they can induce potentially fatal ventricular arrhythmias. 1, 2 Current antiarrhythmic drugs approved for the treatment of atrial fibrillation (AF) are limited in their efficacy and have side-effect profiles that often result in poor patient tolerance. 3 For example, the most efficacious drug currently used to maintain sinus rhythm in patients, amiodarone, has a recurrence rate of 30% after 1 year of treatment and has prominent extracardiac adverse effects. 3, 4 With sotalol or propafenone, the 1-year recurrence rate after treatment is as high as 60%. 3 Thus, a considerable unmet medical need for safe and effective agents against AF exists and ongoing drug development has focused on increased safety by targeting ion channels specifically expressed in the atria.
Clinical Perspective on p 390
Traditionally, small-conductance Ca 2ϩ -activated K ϩ (SK) channels have not been considered important cardiac ion channels. Recently, a small number of articles have linked SK channels to the hearts of mouse, rat, rabbit, and human. [5] [6] [7] [8] Three subtypes of SK channels (SK1-3) exist, and biochemical evidence indicates that SK2 channels are predominantly expressed in the atria of human and mouse hearts as compared with the ventricles. Also, SK1 channels have been reported to be predominantly expressed in the atria of mouse heart. 5, 6 Finally, functional evidence supports the notion that SK channels are more important in atria than in ventricles. 5 The exact role of SK channels in the heart remains uncertain, but they have been suggested to play an important role in atrial repolarization and fibrillation making them an interesting target in AF. 7, 9 However, no systematic investigations have yet been made into the possible proarrhythmic or antiarrhythmic effects of these channels.
SK channels can be blocked by the highly selective 18-aminoacid bee venom toxin apamin as well as several scorpion toxins, such as scyllatoxin and tamapin. 10 Compounds such as tubocurarine and UCL1684 mimic the structural elements of the binding residues on these selective SK neurotoxins, whereas N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (ICA) has been suggested to act by blocking the channels through its chelation to a cation. 11, 12 All the above compounds displace [ 125 I]apamin binding and are considered as pore blockers acting at the apamin binding site. 13 A novel class of selective SK channel inhibitors that do not block the channel pore has recently been described. 13, 14 [ 125 I]Apamin is not displaced by these compounds in binding studies, and they still inhibit SK channels in which point mutations of essential amino acids have disrupted the apamin binding site. 13 NS8593 is an example of a compound from this structural class which indiscriminately modulates all SK1-3 subtypes negatively by decreasing the sensitivity toward Ca 2ϩ . 14, 15 In the present study, we assessed the effects of a negative modulator of SK channels, NS8593, on the atrial effective refractory period (aERP) and the capacity to prevent the induction of AF in isolated guinea pig hearts. We furthermore examined the ability of SK channel inhibition to revert AF in a model of paroxysmal AF in isolated guinea pig hearts. We used 2 structurally unrelated SK channel pore blockers, UCL1684 and ICA, as well as the negative modulator of SK channels NS8593 (Figure 1 ). The finding of the ability of SK inhibition to revert AF in isolated guinea pig heart was subsequently confirmed in an isolated rat and rabbit heart models of paroxysmal AF. Finally, the anti-AF effects of negative modulation of SK channels was tested in vivo in a rat model of paroxysmal AF.
The findings in the present study reveal SK channels as a promising new therapeutic target in the treatment of AF with a decreased risk of ventricular proarrhythmia.
Materials and Methods
All studies were performed in accordance with the Danish guidelines for animal experiments according to the Helsinki declaration. Methods for isolation of single cardiac myocytes, recordings of action potentials, oocyte isolation and injection, in vitro transcription, and 2-electrode voltage clamp recordings can be found in the supplemental material.
Ex Vivo Experiments
The isolated hearts were prepared as earlier described. 16 Four monophasic action potential (MAP) electrodes were placed on the heart surface, 1 on each ventricle and 2 on the left atrium (LA). An ECG was obtained with 9 electrodes placed in the vicinity of the heart. All data were acquired using the 16-channel PowerLab system (AD Instruments, Oxfordshire, United Kingdom). Hearts were electrically stimulated on the right atrium (RA) with 2-ms double-threshold stimuli.
AF Prevention, Guinea Pig
Isolated, perfused female guinea pig hearts from Dunkin Hartley strain (HsdPoc:DH) continuously paced on the right atrium at a rate of 300 bpm were allowed to stabilize and perfused for 30 minutes with either no drug or NS8593 (0.3 mol/L, 1 mol/L, or 3 mol/L). The aERP was measured (10 basic stimuli [S1] followed by premature S2 stimuli applied with 2-ms decrements) immediately before and at the end of the 30-minute period. After the 30 minutes of perfusion with either no drug or NS8593, 1 mol/L acetylcholine (ACh) was added to the perfusate and induction of AF was attempted with S2 stimuli 1 to 3 ms after the end of atrial refractoriness. If S2 stimuli did not elicit AF, the hearts were burst-paced (50 Hz) 10ϫ10 seconds with intervals of 10 seconds. AF was considered prevented if no episodes of AF Ͼ1 minute could be induced by any of these interventions.
AF Reversion, Guinea Pig
Isolated, perfused female guinea pig hearts from Dunkin Hartley strain (HsdPoc:DH) continuously paced on the right atrium (300 bpm) were allowed to stabilize, and aERP was measured. AF was induced by 1 to 3 mol/L ACh combined with S2 stimuli 1 to 3 ms after the end of atrial refractoriness. When sustained AF was obtained (Ͼ2 minutes), either no drug, amiodarone (10 mol/L), ICA (1 mol/L), UCL1684 (1 mol/L), or NS8593 (1 mol/L, Figure 1 . Structures and modes of action of the SK channel inhibitors used in this study. Large structural differences can be observed between all 3 compounds, the negative modulator NS8593, and the 2 pore-blockers ICA and UCL1684. The difference in mode of action of these compounds is emphasized by their ability to displace [ 125 I]apamin binding. Data on NS8593 and UCL1684 are from Sørensen et al 13 and data on ICA is from Gentles et al. 11 3 mol/L, or 10 mol/L) was added to the perfusate. AF was considered reverted if sinus rhythm was obtained within 20 minutes of drug application and if AF could not be reinduced with S2 stimulation or burst pacing after this.
AF Reversion, Rabbit
Isolated, perfused, female rabbit hearts continuously paced on the right atrium (240 bpm) were allowed to stabilize, and aERP was measured. AF was induced by 10 mol/L ACh combined with burst pacing (50 Hz). When sustained AF was obtained (Ͼ2 minutes), 10 mol/L NS8593 was added to the perfusate. AF was considered reverted if sinus rhythm was obtained within 20 minutes of drug application and if AF could not be reinduced with burst pacing after this. After NS8593 application, the drug was allowed to wash out until aERP reached steady state, usually within 20 to 25 minutes. After washing, induction of AF was attempted in 4 of 6 rabbits by burst pacing (50 Hz).
AF Reversion, Rat
Isolated, perfused male rat hearts from the Sprague-Dawley strain (Crl:SD) continuously paced on the right atrium (500 bpm) were allowed to stabilize, and aERP was measured. AF was induced by S2 stimuli 1 to 3 ms after the end of atrial refractoriness. When sustained AF was obtained (Ͼ2 minutes), NS8593 (10 mol/L) was added to the perfusate. AF was considered reverted if sinus rhythm was obtained within 20 minutes of drug application and if AF could not be reintroduced with S2 stimulation or burst pacing after this. After NS8593 application, the compound was allowed to wash out until aERP reached steady state, usually within 20 to 25 minutes. After washing, induction of AF was attempted by S2 stimulation 1 to 3 ms after the end of atrial refractoriness for 5 to 10 minutes. If S2 stimulation did not elicit AF, burst pacing (83 Hz) 10ϫ10 seconds with intervals of 10 seconds was used. AF was considered reintroduced if periods of AF Ͼ5 seconds could be induced by any of these interventions.
In Vivo Experiments
In vivo experiments were conducted in a novel AF model inspired by Haugan et al 17 and Sugiyama et al. 18 Male Sprague-Dawley rats (Crl:SD) rats weighing 350 to 450 g were mebumal-anesthetized (50 mg/kg i.p.), artificially respirated, and kept at 37°C. After thoracotomy and a period of stabilization, short episodes of AF were induced every 2 minutes by open-chest burst pacing (83 Hz) of the RA for 30 seconds with concomitant asphyxia followed by 90 seconds of intrinsic heart rhythm and normal ventilation. MAP recordings were obtained with a MAP electrode placed on the RA, and ECG recordings were obtained with subcutaneous needle electrodes, 2 near the forelimbs and 1 near the left hind limb. Animals were divided into 3 groups receiving intravenous injections of either NS8593 (5 mg/kg), amiodarone (5 mg/kg), or vehicle subsequent to 30 minutes of baseline recordings. AF durations were measured in a blinded fashion. The total duration of AF at all 90-second interburst intervals was measured over a period 30 minutes before injection to establish a baseline AF duration. After injection, the total duration of AF was measured over another period of 30 minutes.
Data Analysis
Data analysis and drawings were performed using GraphPad Prism software (GraphPad Software, San Diego, Calif), SAS 9.2 software (SAS Institute Inc, Cary, NC), Chart 5 software (AD Instruments), or Igor software (WaveMetrics, Lake Oswego, Ore). Continuous data are summarized using the mean and standard deviation. Fisher exact test was used to compare proportions of animals with protection against AF by treatment with probability values adjusted for multiple comparisons with the Bonferroni method (probability values multiplied with the number of comparisons). One-way ANOVA with Tukey post hoc test was used to compare mean values of aERP and QT-interval by concentration of NS8593 and for comparing AFdurations normalized to baseline values for the 3 different treatment regimens in vivo, and the paired Student t test was applied for the selectivity data. Values of PϽ0.05 were considered significant. The small sample sizes used in this study are a limitation with regard to the statistical analysis (Figure 1 ).
Drugs and Solutions
Unless otherwise mentioned, all the chemicals used were of analytic grade and were obtained from Sigma-Aldrich. NS8593, UCL1684, and ICA were synthesized at NeuroSearch A/S, Ballerup, Denmark. Except from amiodarone, drugs were dissolved in dimethyl sulfoxide as concentrated stock solutions of 10 mmol/L and diluted directly into the perfusion solution to yield the final concentration for the ex vivo experiments. Amiodarone liquid for injection 50 mg/mL produced by Sanofi-Aventis A/S and glucose liquid for infusion 50 mg/mL produced by B. Braun Melsungen AG was obtained from a Danish pharmacy. The vehicle solution for amiodarone liquid for injection 50 mg/mL consisted of polysorbate 80, benzilic alcohol and water (10:10:80, v/v/v), which was diluted in glucose liquid for infusion to a final concentration of 5 mg/mL. Glucose liquid for infusion with 5% cremophor was used as vehicle for the in vivo experiments.
Results
If aERP is shortened, the likelihood that circulating impulses perpetuate is dramatically increased. 19 In the ex vivo guinea pig model of AF that we use in this study, ACh is added to the perfusate in order to shorten aERP, thus providing an arrhythmic substrate. With aERP thus shortened, sustained AF can be elicited by electric stimulation unless measures are taken to terminate it. In Figure 2 , an example of sustained AF is shown along with an example of how NS8593 terminates AF and prevents its reinduction.
SK Channel Inhibition Prevents AF Induction in Ex Vivo Guinea Pig Heart
To examine the effect of NS8593 on aERP and the capacity to prevent AF, isolated guinea pig hearts were perfused with different concentrations of the negative modulator of SK channels NS8593 ( Figure 3 ). Increasing concentrations of NS8593 (0.3 mol/L, 1 mol/L, and 3 mol/L) prolonged aERP (overall probability value Ͻ0.001) by 13.1Ϯ7.8%, PϽ0.05, nϭ4; 18.9Ϯ3.4%, PϽ0.01, nϭ3), and 37.1Ϯ7.7%, PϽ0.001, nϭ4), respectively, compared with controls (0.7Ϯ4.4%, nϭ4) ( Figure 3B ). These effects are believed to be atrial-selective because no effect on QT-interval was observed in any of the concentrations tested ( Figure 3A and 3B). The increased aERP was associated with a protection against the induction of AF; in all of the time matched control experiments sustained AF was inducible (nϭ7) (Figure 2 ), whereas increasing concentrations of NS8593 (0.3 mol/L, 1 mol/L, and 3 mol/L) protected against induction of AF (overall probability valueϭ0.03) in 43% (Pϭ0.19, nϭ7), 80% (PϽ0.05, nϭ5), and 100% (PϽ0.01, nϭ4) of preparations ( Figure 3A and 3C ). Of the drug-treated hearts, only 1 from the 0.3 mol/L group developed AF without burst pacing. In the rest of the drug-treated hearts in which AF could be induced, burst pacing was necessary to elicit the AF.
In comparison, the gentler AF induction protocol of S2 stimulation was sufficient to elicit AF in controls, suggesting a decreased vulnerability to AF even at the lowest dose of NS8593, although complete protection was not provided.
SK Channel Inhibition Reverts Acutely Induced AF in Ex Vivo Guinea Pig Heart
Drugs such as sotalol that are effective in preventing AF are not necessarily effective for conversion of AF to sinus rhythm. 20 Therefore, we next examined the capacity of SK channel inhibition to revert sustained AF. When sustained AF (Ͼ2 minutes) had been induced in the time matched controls, it lasted for the duration of the experiment (Ͼ45 minutes, nϭ7) ( Figures  2 and 4) . In 1 of 7 controls, AF reverted spontaneously after 3 minutes but could be easily reintroduced with S2 stimulation. In hearts perfused with increasing concentrations of NS8593 (1 mol/L, 3 mol/L, and 10 mol/L), AF was reverted and nonreinducible (overall probability value Ͻ0.001) in 33%, Pϭ0.58, nϭ6; 83%, PϽ0.01, nϭ6; and 100%, PϽ0.001, nϭ6), respectively, of the hearts ( Figure 4B ). aERP is prolonged in the presence of 3 mol/L NS8593 with no effect on QT interval or ventricular APD. Addition of 1 mol/L ACh blocks AV node conduction and shortens aERP, but this heart is protected against AF induction by S2 stimulation and burst pacing. B, NS8593 concentrationdependently increases aERP with no effect on QT interval in concentrations from 0.3 to 3 mol/L. C, NS8593 concentrationdependently protects against the induction of AF.
Two other SK channel inhibitors, UCL1684 and ICA, with pore-blocking properties, as opposed to the inhibition on Ca 2ϩ -sensitivity exerted by NS8593, also reverted and protected against AF (overall probability value Ͻ0.001) ( Figure  4C and Figure 1 ). In 100% of hearts perfused with 1 mol/L ICA or 1 mol/L UCL1684, AF was reverted and could not be reinduced (PϽ0.01, nϭ5 in both cases).
The effects of SK channel inhibition were comparable to those seen in hearts perfused with 10 mol/L amiodarone (reversion of and protection against AF in 100% of the hearts) ( Figure 4C ). Amiodarone is normally used as a last-resort agent that dampens electric activity in the heart by an unspecific block of multiple ion channels (I Na , I Kr , I Ks , and L-type Ca 2ϩ channels) and is the most efficient presently available agent for maintenance of sinus rhythm, but the compound has prominent extra-cardiac adverse effects and complicated pharmacokinetics that limit widespread application. 20
SK Channel Inhibition Reverts Acutely Induced AF in Ex Vivo Rat Heart
To confirm the antiarrhythmic effects of SK inhibition seen in guinea pig, we examined the capability of 10 mol/L NS8593 to revert AF in a rat ex vivo model. Sustained AF was induced with S2 stimulation in all hearts before drug application (nϭ6) ( Figure 5A and 5C ). After application of 10 mol/L NS8593, AF was reverted (overall probability value Ͻ0.001) and could not be reinduced in any (PϽ0.001, nϭ6) of the hearts. After a washout period of 20 to 25 minutes, during which aERP progressively shortened until reaching a steady state, AF could be reinduced in all hearts (nϭ6) ( Figure 5A and 4C ). Application of 10 mol/L NS8593 prolonged aERP (overall probability value Ͻ0.001) in the rat hearts from 15.5Ϯ3.8 ms in the control situation to 43.5Ϯ7.0 ms (PϽ0.001, nϭ6) ( Figure 5B ). After washout, aERP was shortened to 23.0Ϯ5.2 ms, which was not significantly different from the control situation ( Figure 5B ).
SK Channel Inhibition Reverts Acutely Induced AF in Ex Vivo Rabbit Heart
The capability of 10 mol/L NS8593 to revert AF was further examined in a rabbit ex vivo model. Sustained AF was induced with ACh and burst pacing in all hearts (nϭ6) ( Figure 6 ). After application of 10 mol/L NS8593, AF was reverted (overall probability value Ͻ0.001) and could not be reinduced in any (PϽ0.01, nϭ6) of the hearts. After a washout period of 20 to 25 minutes, AF could be reinduced in 3 of 4 hearts(Pϭ0.06), which was not significantly different from the control situation (Pϭ0.8). In 2 hearts (initial experiments), a washout was not conducted. The effects on aERP were as follows (overall probability value Ͻ0.001): Before drug application aERP was 75Ϯ9.ms, 10 mol/L ACh shortened aERP to 39Ϯ7 ms (PϽ0.01), coapplication of 10 mol/L NS8593 increased aERP to 110Ϯ8 ms (PϽ0.001), and washout with 10 mol/L ACh could only partly bring down aERP to 72Ϯ15 ms which was significantly shorter than when SK inhibitor was present (PϽ0.01) but not significantly shorter than when no drug was present. However, the washout of NS8593 was sufficient to elicit AF in 3 of 4 hearts.
SK Channel Inhibition Protects Against Acutely Induced AF in Rat In Vivo
The ex vivo data clearly show antiarrhythmic potential with SK channel inhibition and to further substantiate these findings, we used a rat in vivo model of AF. The effects of SK Figure 5 . AF reversion in isolated, perfused rat heart. A, Representative recordings from isolated, perfused rat heart of ECG and MAPs from left ventricle and LA in the presence of no drug, 10 mol/L NS8593, and after washing combined with S2 stimulation and with 10 mol/L NS8593 combined with burst pacing. S2 stimulation elicits sustained AF in the presence of no compound. Perfusion with 10 mol/L NS8593 terminates AF and protects against the reinduction of AF by S2 stimulation and by burst pacing. After washing, AF can be reinduced by S2 stimulation. B, Application of 10 mol/L NS8593 prolongs aERP in the rat hearts from 15.5Ϯ3.8 ms in the control situation to 43.5Ϯ7.0 ms (PϽ0.001, nϭ6). After washout, aERP is shortened to 23.0Ϯ5.2 ms, which is not significantly different from the control situation. C, S2 stimulation elicits sustained AF in the presence of no compound in all hearts. Perfusion with 10 mol/L NS8593 terminates AF and protects against the reinduction of AF by S2 stimulation and by burst pacing in all hearts. After washing, AF can be reinduced by S2 stimulation in all hearts.
channel inhibition in this model were compared with the effects of amiodarone. The average duration of AF episodes elicited by burst pacing at baseline was 2.6 seconds. The effects on the duration of AF were as follows (overall probability value Ͻ0.001): Injection of vehicle did not change AF durations significantly compared to baseline recordings (96.3%Ϯ33.2%, nϭ5, Pϭ0.80) (Figure 7) . The overall duration of AF normalized to baseline recordings was significantly shorter in the NS8593 treated group and in the group treated with amiodarone (23.2%Ϯ20.0%, PϽ0.001, nϭ5, and 26.2%Ϯ17.9%, PϽ0.001, nϭ5, respectively) compared with the vehicle-treated group (96.3%Ϯ33.2%, nϭ5). There were no significant differences in the effects on AF duration in the groups treated with NS8593 or amiodarone.
NS8593 Is a Selective Inhibitor of SK Channels
Selectivity data on NS8593 have been published on recombinant big-and intermediate-conductance Ca 2ϩ -activated K ϩ channels (BK and IK channels, respectively), K v 7.2, K v 7.3, K v 11.1, rNa v 1.2 as well as native voltage-dependent Na ϩ , Ca 2ϩ , and K ϩ channels in rat embryonic dorsal root ganglion neurons. 14 To obtain further evidence for a cardiac specific SK channel inhibition of NS8593, additional selectivity data toward K v 1.4, K v 1.5, K v 4.3, K v 7.1, K ir 2.1, and GIRK3.1/3.4 coexpressed with M2-type ACh receptors were obtained (Figure 8 ). NS8593 show no effect in any of these cardiac relevant channels in concentrations of 10 mol/L.
Discussion

Antiarrhythmic Properties of SK Channel Inhibition
In the present study, we provide evidence for the first time that pharmacological inhibition of SK channels can prevent and revert AF in different models of AF in guinea pig, rat, and rabbit.
Theories of the mechanism of AF involve 2 main processes: 1 or more rapidly depolarizing foci that function as triggers of arrhythmia, and a fibrillation-prone atrium that allows reentry involving 1 or more circuits. 20 Typically, the triggers of AF originate in the pulmonary vein-atrial junctions. 21, 22 Single-and multiple-circuit reentry play key roles in the mechanism of AF. 19, 20, 22, 23 The aERP plays a crucial role in reentry-a long aERP increases the chances that a circulating impulse encounters refractory tissue and subsequently terminates. Both single-and multiple-circuit reentry should be amenable to drugs that prolong the aERP and the primary approach to treating AF is therefore to increase aERP. Episodes of AF leads to electric remodeling of the atria in a manner that shortens atrial action potential duration (APD) and aERP and promotes AF initiation and maintenance. 24 Our data demonstrate that SK inhibition prevents and reverts AF in acute models of AF, probably by prolonging aERP, thereby inhibiting reentry. In neither the ex vivo nor the in vivo experiments did we observe any proarrhythmic effects by prolonging aERP. Pharmacological inhibition of SK channels combined with S2-stimulation did not elicit any episodes of AF ex vivo. Similarly, pharmacological inhibition of SK channels in vivo decreased AF susceptibility to burst pacing rather than increasing it. Importantly, it should be noted, that from a functional point of view SK channel inhibition appeared atria-selective since no effect in QT intervals was observed in the tested concentrations of NS8593.
The involvement of SK channels in AF genesis is substantiated by data from Ö zgen et al, which suggest that SK2 channels are involved in atrial remodeling and that upregulation of these channels in the pulmonary vein-atrial junctions provides a basis for evolution of an arrhythmogenic substrate by shortening APD. 7 Furthermore, very recently a link between SNP polymorphisms in the gene encoding SK3 and AF in humans has been found. 25 A different piece of evidence for a role of SK channels in AF has been provided by Li et al, 9 who have demonstrated that SK2 knockout mice have prolonged atrial APD, show S2-inducible AF, and atrial early afterdepolarizations under appropriate conditions. Prolongation of atrial APD would normally not be expected to promote AF, and the electrophysiological remodeling in patients with AF involves shortening of APD and thereby the aERP. Thus, Li et al show that loss of function of SK2 promotes AF in mice, whereas Ö zgen et al suggest that increased SK2 function provides an arrhythmogenic substrate in rabbits, and we demonstrate that inhibition of SK channels prolongs aERP and prevents and reverts AF in rabbit s, guinea pigs and rats.
This apparent discrepancy may be insignificant due to the fact that both augmentation and reduction of repolarization in Figure 6 . A, Application of 10 mol/L ACh shortens aERP in the rabbit hearts from 75Ϯ9 ms to 39Ϯ7 ms (PϽ0.01, nϭ6). Coapplication of 10 mol/L NS8593 with ACh increases aERP to 110Ϯ8 ms (PϽ0.001), and washout with 10 mol/L ACh decreases aERP to 72Ϯ15 ms, which is significantly shorter than with SK inhibitor present (PϽ0.01) but not significantly shorter than when no drug was present. However, the washout of NS8593 was sufficient to elicit AF in 3 of 4 hearts as shown in B, in which burst pacing elicits sustained AF in the presence of 10 mol/L ACh in all hearts. Coperfusion with 10 mol/L NS8593 terminates AF and protects against the reinduction of AF by burst pacing in all hearts (Pϭ0.002, nϭ6). After washing with ACh, AF can be reinduced by burst pacing in 3 of 4 hearts (Pϭ0.06), which is a significant increase (Pϭ0.03) and not significantly different from the control situation (Pϭ0.4).
principle can lead to arrhythmogenesis. 26, 27 Also, in the study of Li et al, SK2 channels were completely absent in the mice, whereas indirect mechanisms of AF cannot be excluded. Furthermore, there is a difference in the species used, as Li et al used mice, Ö zgen et al used rabbits, and we have used rabbit, guinea pig, and rat. Another possible explanation could be the fact that mice tend to develop AF episodes of focal origin maintained primarily by early and/or late afterdepolarizations, whereas it is still controversial and unclear whether triggered activity contributes to AF maintenance in large-animal models and patients. This may explain why SK2 knockout mice develop AF as the result of APD prolongation and early afterdepolarization evolution, whereas in rabbits with electric remodeling the higher SK2 membrane expression likely promotes AF by providing a substrate for AF. Variable expression of ion channels, as well as differences in heart rate and action potential morphology in mice compared with other species, might also explain the dissimilar effects of enhancing and reducing SK current observed in different species.
Apamin and SK Channel Inhibition
Apamin is considered the state-of-the art blocker of SK channels. However, evidence for the effects of apamin in cardiac preparations are conflicting; in 2003 Xu et al 5 reported a significant prolongation of APD from human and mouse cardiac myocytes that was significantly greater in atrial myocytes as compared with ventricular myocytes, whereas Nagy et al 28 in 2009 saw no effects of apamin in rat and dog atrial and ventricular multicellular preparations and in isolated cardiomyocytes. This led Nagy et al to conclude that SK channels, though present, are not active and do not contribute to cardiac repolarization under normal physiolog-ical conditions. In preliminary experiments, we also tested the effects of apamin in atrial myocytes from guinea pigs and in guinea pig Langendorff hearts with induced AF. In atrial myocytes, apamin only showed a slight increase in APD at 2 Hz pacing rate and no significant effect at 1 Hz. Concentrations of apamin as high as 1 mol/L did not revert sustained AF in guinea pig Langendorff hearts (nϭ2). This lack of effect of apamin could have a number of explanations. At supramaximal concentrations (1 mol/L) apamin has previously been found to leave almost half of the SK currents unblocked in Chinese hamster ovary cells stably expressing SK1-3. 29 There can be several possible explanations to this; for example, auxiliary subunits exist that can prevent apamin binding, or apamin block can be modulated by phosphorylation, or apamin has separate mechanisms for binding and blocking that allow the channel to be in a conducting state even when apamin is bound, as opposed to other blockers of SK channels. 29, 30 Thus, apamin may constitute its own third class of SK channel inhibitors different from both the negative modulators and the other pore blockers. Also, the existence of an apamin-and scyllatoxin-insensitive isoform of the human SK3 channel has been reported. 31 It seems possible that SK channels in the heart have properties that decrease the blocking effects of apamin, making apamin unsuited for addressing SK currents in the heart.
Potential for SK Inhibition in the Treatment of AF
The use of conventional antiarrhythmic compounds has been limited by potentially fatal ventricular arrhythmias. Consequently, ongoing drug development has focused on increasing safety by developing atrial-specific agents. Atrial selectivity can be achieved by targeting ion channels that are selectively expressed in the atria or by blocking Na ϩ channels in a state dependent manner that favors blocking of atrial rather than ventricular action potentials or that are effective at rapid rhythms as AF. The number of known atrial-specific ion channels has until recently been limited to I Kur and I KACh . Several compounds have been developed that show atrial selectivity. Vernakalant and AZD7009 affect cardiac Na ϩ channels and a number of K ϩ channels including I Kur and I KACh and have proven effective in terminating AF in patients. [32] [33] [34] [35] [36] [37] Other atrial-selective compounds effective in treating AF in preclinical models are AVE0118 and NIP-142. Both AVE0118 and NIP-142 block several K ϩ channels and NIP-142 blocks Ca 2ϩ and Na ϩ channels as well. 38 -47 Because all of these atrial-selective compounds exert their effect by a multiple-channel block, it would be reasonable to think that the SK inhibitors used in this study are not solely affecting SK channels. However, selectivity data on NS8593 show no effect of the compound on other ion channels than SK channels. In addition, 2 potent SK channel pore blockers, UCL1684 and ICA, structurally unrelated to NS8593 and with a different mode of action than NS8593, exert antiarrhythmic effects comparable to those of NS8593. In combination with the selectivity data, this suggests that the antiarrhythmic effect of NS8593 is primarily a result of SK channel inhibition. Within the last few years, biochemical evidence has emerged that SK channels are predominantly expressed in the atria compared with the ventricles. 5, 6 In the present study, we show that a selective negative modulator of SK channels prolongs aERP concentration-dependently and is able to revert and prevent the induction of AF without affecting the QT-interval.
Thus, the use of specific inhibitors of SK channels may offer a new therapeutic opportunity in the treatment of AF with a decreased risk of ventricular proarrhythmia.
Conclusion
In the present study, we show that 3 structurally different SK channel inhibitors have antiarrhythmic properties in 3 different species both ex vivo and in vivo. From a mechanistic point of view, the negative modulation of SK channels prolongs aERP concentration-dependently and is able to revert and prevent against the induction of AF without affecting the QT-interval.
Hence, although further studies are needed to address the clinical relevance of these findings, SK channels offer a promising new therapeutic target in the treatment of AF with a decreased risk of ventricular proarrhythmia.
